{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:36:29Z","timestamp":1788057389771,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00874-z","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:47:39Z","timestamp":1766040459000},"page":"15-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans"],"prefix":"10.1007","volume":"15","author":[{"given":"Peter J.","family":"Goadsby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia K.","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f4me","family":"Mawet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Lanteri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim Patrick","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Sumelahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita Sanchez","family":"del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"del Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"874_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s10194-025-02069-1","volume":"26","author":"M Sanchez-Del-Rio","year":"2025","unstructured":"Sanchez-Del-Rio M, Garc\u00eda-Azor\u00edn D, Peral C, Armada B, Irimia-Sieira P, Porta-Etessam J. Prevalence, disability, and economic impact of migraine in Spain: a nationwide population-based study. J Headache Pain. 2025;26:117. https:\/\/doi.org\/10.1186\/s10194-025-02069-1.","journal-title":"J Headache Pain"},{"key":"874_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23:34. https:\/\/doi.org\/10.1186\/s10194-022-01402-2.","journal-title":"J Headache Pain"},{"key":"874_CR3","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"874_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","volume":"14","author":"N Karsan","year":"2018","unstructured":"Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14:699\u2013710. https:\/\/doi.org\/10.1038\/s41582-018-0098-4.","journal-title":"Nat Rev Neurol"},{"key":"874_CR5","doi-asserted-by":"publisher","first-page":"333102423120637","DOI":"10.1177\/03331024231206376","volume":"43","author":"RH Christensen","year":"2023","unstructured":"Christensen RH, Eigenbrodt AK, Ashina H, Steiner TJ, Ashina M. What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies. Cephalalgia. 2023;43:3331024231206376. https:\/\/doi.org\/10.1177\/03331024231206376.","journal-title":"Cephalalgia"},{"key":"874_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21.","journal-title":"Neurology"},{"key":"874_CR7","first-page":"53","volume":"9","author":"S Landy","year":"2007","unstructured":"Landy S, DeRossett SE, Rapoport A, Rothrock J, Ames MH, McDonald SA, et al. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan\/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. MedGenMed. 2007;9:53.","journal-title":"MedGenMed"},{"key":"874_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12883-025-04039-1","volume":"25","author":"RE Shapiro","year":"2025","unstructured":"Shapiro RE, Viktrup L, Muenzel EJ, Buse DC, Zagar AJ, Ashina S, et al. Stigmatizing attitudes toward people with migraine by people without active migraine: results of the OVERCOME (US) study. BMC Neurol. 2025;25:103. https:\/\/doi.org\/10.1186\/s12883-025-04039-1.","journal-title":"BMC Neurol"},{"key":"874_CR9","doi-asserted-by":"publisher","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2.","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"874_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"key":"874_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40259-022-00530-0","volume":"36","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, Silberstein SD. Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. 2022;36:341\u201358. https:\/\/doi.org\/10.1007\/s40259-022-00530-0.","journal-title":"BioDrugs"},{"key":"874_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neurol.2024.10.006","volume":"181","author":"M Lanteri-Minet","year":"2025","unstructured":"Lanteri-Minet M, Lucas C. Update of French migraine epidemiology: a narrative review. Rev Neurol (Paris). 2025;181:114\u201323. https:\/\/doi.org\/10.1016\/j.neurol.2024.10.006.","journal-title":"Rev Neurol (Paris)"},{"key":"874_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703\u201311. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x.","journal-title":"Eur J Neurol"},{"key":"874_CR14","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024;23:344\u201381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3.","DOI":"10.1016\/S1474-4422(24)00038-3"},{"key":"874_CR15","doi-asserted-by":"publisher","first-page":"333102424125266","DOI":"10.1177\/03331024241252666","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener H-C, Ashina M, Al-Khazali HM, Ashina S, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024;44:3331024241252666. https:\/\/doi.org\/10.1177\/03331024241252666.","journal-title":"Cephalalgia"},{"key":"874_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688\u201395. https:\/\/doi.org\/10.1212\/WNL.0000000000001256.","journal-title":"Neurology"},{"key":"874_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157\u201368. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01217.x.","journal-title":"Headache"},{"key":"874_CR18","doi-asserted-by":"publisher","first-page":"333102425132150","DOI":"10.1177\/03331024251321500","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, Al-Khazali HM, Ambrosini A, Ashina S, et al. Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia. 2025;45:3331024251321500. https:\/\/doi.org\/10.1177\/03331024251321500.","journal-title":"Cephalalgia"},{"key":"874_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015.","journal-title":"Physiol Rev"},{"key":"874_CR20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/head.14968","volume":"65","author":"I Peles","year":"2025","unstructured":"Peles I, Shneyour RS, Levanon E, Steen YM, Salameh IA, Gordon M, et al. Cardiovascular risk and triptan usage among patients with migraine. Headache. 2025;65:1095\u2013106. https:\/\/doi.org\/10.1111\/head.14968.","journal-title":"Headache"},{"key":"874_CR21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.297.13.1443","volume":"297","author":"JL Brandes","year":"2007","unstructured":"Brandes JL, Kudrow D, Stark SR, O\u2019Carroll CP, Adelman JU, O\u2019Donnell FJ, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297:1443\u201354. https:\/\/doi.org\/10.1001\/jama.297.13.1443.","journal-title":"JAMA"},{"key":"874_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-4-10","author":"AV Krymchantowski","year":"2004","unstructured":"Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 2004. https:\/\/doi.org\/10.1186\/1471-2377-4-10.","journal-title":"BMC Neurol"},{"key":"874_CR23","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1468-2982.2008.01654.x","volume":"28","author":"J Schoenen","year":"2008","unstructured":"Schoenen J, Klippel ND, Giurgea S, Herroelen L, Jacquy J, Louis P, et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia. 2008;28:1095\u2013105. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01654.x.","journal-title":"Cephalalgia"},{"key":"874_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener H-C, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17:501\u201314. https:\/\/doi.org\/10.1038\/s41582-021-00509-5.","journal-title":"Nat Rev Neurol"},{"key":"874_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03259-7","author":"H Abdelmonem","year":"2023","unstructured":"Abdelmonem H, Abdelhay HM, Abdelwadoud GT, Alhosini ANM, Ahmed AE, Mohamed SW, et al. The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. BMC Neurol. 2023. https:\/\/doi.org\/10.1186\/s12883-023-03259-7.","journal-title":"BMC Neurol"},{"key":"874_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/head.13069","volume":"57","author":"F Puledda","year":"2017","unstructured":"Puledda F, Goadsby PJ. An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache. 2017;57:685\u201391. https:\/\/doi.org\/10.1111\/head.13069.","journal-title":"Headache"},{"key":"874_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01204-4","author":"X Moisset","year":"2020","unstructured":"Moisset X, Pereira B, Andrade DC, Fontaine D, Lant\u00e9ri-Minet M, Mawet J. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2020. https:\/\/doi.org\/10.1186\/s10194-020-01204-4.","journal-title":"J Headache Pain"},{"key":"874_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04291-5","author":"AZ Alnajjar","year":"2025","unstructured":"Alnajjar AZ, Mustafa MMM, Abdelsalam OK, Sharabati I, Hassan AK, Allam M, et al. Efficacy and safety of remote electrical neuromodulation in migraine: a comprehensive systematic review and meta-analysis. BMC Neurol. 2025. https:\/\/doi.org\/10.1186\/s12883-025-04291-5.","journal-title":"BMC Neurol"},{"key":"874_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"874_CR30","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.neurol.2025.06.006","volume":"181","author":"C Lucas","year":"2025","unstructured":"Lucas C, Raclot V, Gugenheim M, Lefebvre H, Braithwaite B, Ducros A. Migraine management in France: practices of general practitioners and neurologists. Rev Neurol (Paris). 2025;181:652\u201366. https:\/\/doi.org\/10.1016\/j.neurol.2025.06.006.","journal-title":"Rev Neurol (Paris)"},{"key":"874_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000073859","volume":"50","author":"D Cologno","year":"2003","unstructured":"Cologno D, Manzoni GC. An epidemiological study of migraine with aura in the San Severo General Population: a pilot research project of cooperation between neurologists and general practitioners. Eur Neurol. 2003;50:195\u20139. https:\/\/doi.org\/10.1159\/000073859.","journal-title":"Eur Neurol"},{"key":"874_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114\u201325. https:\/\/doi.org\/10.1177\/0333102413500727.","journal-title":"Cephalalgia"},{"key":"874_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"H-C Diener","year":"2011","unstructured":"Diener H-C, Barbanti P, Dahl\u00f6f C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573\u201384. https:\/\/doi.org\/10.1177\/0333102410388435.","journal-title":"Cephalalgia"},{"key":"874_CR34","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(08)61626-8.","journal-title":"Lancet"},{"key":"874_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"C-P Yang","year":"2021","unstructured":"Yang C-P, Liang C-S, Chang C-M, Yang C-C, Shih P-H, Yau Y-C, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544.","journal-title":"JAMA Netw Open"},{"key":"874_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080107","author":"WK Karlsson","year":"2024","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ. 2024. https:\/\/doi.org\/10.1136\/bmj-2024-080107.","journal-title":"BMJ"},{"key":"874_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080107","volume":"386","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Goadsby PJ. Rapid response to: Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ. 2024;386:e080107. https:\/\/doi.org\/10.1136\/bmj-2024-080107.","journal-title":"BMJ"},{"key":"874_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamaneurol.2023.5549","volume":"81","author":"CL Petersen","year":"2024","unstructured":"Petersen CL, Hougaard A, Gaist D, Hallas J. Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol. 2024;81:248. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5549.","journal-title":"JAMA Neurol"},{"key":"874_CR39","doi-asserted-by":"publisher","first-page":"333102424122860","DOI":"10.1177\/03331024241228605","volume":"44","author":"HC Diener","year":"2024","unstructured":"Diener HC, May A. New migraine drugs: a critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication. Cephalalgia. 2024;44:3331024241228605. https:\/\/doi.org\/10.1177\/03331024241228605.","journal-title":"Cephalalgia"},{"issue":"Suppl 2","key":"874_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16434","volume":"31","author":"R-J Wilcha","year":"2024","unstructured":"Wilcha R-J, Afridi SK, Barbanti P, Diener HC, J\u00fcrgens TP, Lanteri-Minet M, et al. Sumatriptan-naproxen sodium in migraine: a review. Eur J Neurol. 2024;31(Suppl 2):e16434. https:\/\/doi.org\/10.1111\/ene.16434.","journal-title":"Eur J Neurol"},{"key":"874_CR41","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1468-2982.2008.01806.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD, et al. Consistency of response to sumatriptan\/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia. 2009;29:826\u201336. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01806.x.","journal-title":"Cephalalgia"},{"key":"874_CR42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/01.wnl.0000316800.22949.20","volume":"71","author":"SD Silberstein","year":"2008","unstructured":"Silberstein SD, Mannix LK, Goldstein J, Couch JR, Byrd SC, Ames MH, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71:114\u201321. https:\/\/doi.org\/10.1212\/01.wnl.0000316800.22949.20.","journal-title":"Neurology"},{"key":"874_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4065\/82.1.61","volume":"82","author":"P Winner","year":"2007","unstructured":"Winner P, Cady RK, Ruoff GE, Frishberg BM, Alexander WJ, Zhang Y, et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc. 2007;82:61\u20138. https:\/\/doi.org\/10.4065\/82.1.61.","journal-title":"Mayo Clin Proc"},{"key":"874_CR44","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1526-4610.2007.00790.x","volume":"47","author":"T Smith","year":"2007","unstructured":"Smith T, Blumenthal H, Diamond M, Mauskop A, Ames M, McDonald S, et al. Sumatriptan\/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache. 2007;47:683\u201392. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00790.x.","journal-title":"Headache"},{"key":"874_CR45","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1526-4610.2009.01606.x","volume":"50","author":"LJ Haberer","year":"2010","unstructured":"Haberer LJ, Walls CM, Lener SE, Taylor DR, McDonald SA. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010;50:357\u201373. https:\/\/doi.org\/10.1111\/j.1526-4610.2009.01606.x.","journal-title":"Headache"},{"key":"874_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1526-4610.2008.01310.x","volume":"48","author":"VT Martin","year":"2008","unstructured":"Martin VT, Lipton RB. Epidemiology and biology of menstrual migraine. Headache. 2008;48:124\u201330. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01310.x.","journal-title":"Headache"},{"key":"874_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0333102413507637","volume":"34","author":"KG Vetvik","year":"2014","unstructured":"Vetvik KG, Macgregor EA, Lundqvist C, Russell MB. Prevalence of menstrual migraine: a population-based study. Cephalalgia. 2014;34:280\u20138. https:\/\/doi.org\/10.1177\/0333102413507637.","journal-title":"Cephalalgia"},{"key":"874_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012723","author":"DS Casteren","year":"2021","unstructured":"Casteren DS, Verhagen IE, Arend BWH, Zwet EW, MaassenVanDenBrink A, Terwindt GM. Comparing perimenstrual and nonperimenstrual migraine attacks using an e-diary. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000012723.","journal-title":"Neurology"},{"key":"874_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/AOG.0b013e3181a98e4d","volume":"114","author":"LK Mannix","year":"2009","unstructured":"Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen. Obstet Gynecol. 2009;114:106\u201313. https:\/\/doi.org\/10.1097\/AOG.0b013e3181a98e4d.","journal-title":"Obstet Gynecol"},{"key":"874_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/WCO.0000000000001372","volume":"38","author":"M Ghadiri-Sani","year":"2025","unstructured":"Ghadiri-Sani M. Migraine in women: a review. Curr Opin Neurol. 2025;38:271\u20136. https:\/\/doi.org\/10.1097\/WCO.0000000000001372.","journal-title":"Curr Opin Neurol"},{"key":"874_CR51","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/jwh.2013.4577","volume":"23","author":"VT Martin","year":"2014","unstructured":"Martin VT, Ballard J, Diamond MP, Mannix LK, Derosier FJ, Lener SE, et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. J Womens Health (Larchmt). 2014;23:389\u201396. https:\/\/doi.org\/10.1089\/jwh.2013.4577.","journal-title":"J Womens Health (Larchmt)"},{"key":"874_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, et al. Migraine. Nat Rev Dis Primers. 2022;8:2. https:\/\/doi.org\/10.1038\/s41572-021-00328-4.","journal-title":"Nat Rev Dis Primers"},{"key":"874_CR53","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1526-4610.2009.01458.x","volume":"49","author":"NT Mathew","year":"2009","unstructured":"Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49:971\u201382. https:\/\/doi.org\/10.1111\/j.1526-4610.2009.01458.x.","journal-title":"Headache"},{"key":"874_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care (2nd edition). J Headache Pain. 2019;20:57. https:\/\/doi.org\/10.1186\/s10194-018-0899-2.","journal-title":"J Headache Pain"},{"key":"874_CR55","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/0333102413508242","volume":"34","author":"S Silberstein","year":"2014","unstructured":"Silberstein S, McDonald SA, Goldstein J, Aurora S, Lener SE, White J, et al. Sumatriptan\/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. Cephalalgia. 2014;34:268\u201379. https:\/\/doi.org\/10.1177\/0333102413508242.","journal-title":"Cephalalgia"},{"key":"874_CR56","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/head.12214","volume":"54","author":"SH Landy","year":"2014","unstructured":"Landy SH, Cady RK, Nelsen A, White J, Runken MC. Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan\/naproxen sodium combination. Headache. 2014;54:640\u201354. https:\/\/doi.org\/10.1111\/head.12214.","journal-title":"Headache"},{"key":"874_CR57","doi-asserted-by":"publisher","first-page":"ITC5","DOI":"10.7326\/0003-4819-159-9-201311050-01005","volume":"159","author":"EA MacGregor","year":"2013","unstructured":"MacGregor EA. Migraine. ACP J Club. 2013;159:ITC5\u2013ITC1. https:\/\/doi.org\/10.7326\/0003-4819-159-9-201311050-01005.","journal-title":"ACP J Club"},{"key":"874_CR58","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","volume":"270","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, L\u00f6f E, et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023;270:5692\u2013710. https:\/\/doi.org\/10.1007\/s00415-023-11880-2.","journal-title":"J Neurol"},{"key":"874_CR59","unstructured":"NICE. Diagnosis and management of headaches in young people and adults. Update December 2021. https:\/\/www.nice.org.uk\/guidance\/cg150. Accessed Nov 3, 2025."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00874-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:52:05Z","timestamp":1768398725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00874-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00874-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Apart from the honoraria related to the participation in the Delphi questionnaire, Peter J. Goadsby, Alexandra J. Sinclair, Shazia K Afridi, Christian Lucas, Jer\u00f4me Mawet, Michel Lanteri-Minet, Xavier Moisset, Hans Christoph Diener, Charly Gaul, Tim Patrick J\u00fcrgens, Marja-Liisa Sumelahti, Margarita Sanchez del Rio, Patricia del Pozo-Rosich, Antonio Russo, and Piero Barbanti have nothing relevant to declare regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Delphi exercise was conducted by collecting answers from the co-authors, and not from patients or anonymous healthcare providers. It was a discussion technique aimed at reaching a consensus. No new data or studies were considered, just the co-author expertise and the existing literature, and for this reason, ethical approval was not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}